Effect of combined use of ivermectin and colchicine in COVID-19 patients

Sayed, Rania Gamal El; Hafez, Amr Fouad; Haggag, Adham Magdy; Alhadidy, Mohamed A.

doi:10.1080/11101849.2022.2089518

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of colchicine is associated with a significant decrease in days of oxygen need, length of intensive care unit stays, less need for mechanical ventilation, accelerated recovery, and reduced mortality when the doses are 1.5 mg daily for 5 days, then 1 mg for 14 days. 32 …”

Section: Discussionmentioning

confidence: 99%

“…It is very likely that the younger Brazilian patients in the Lopes et al study were also of lower weight, which automatically increases the dose of colchicine per kg. 31 It should be expected that in developing countries 29 , 31 , 32 patients have a lower body mass index index than those in Europe or the United States, Canada, and Australia, thus a better effect of colchicine should be expected.…”

Section: Discussionmentioning

confidence: 99%

“…31 The use of colchicine is associated with a significant decrease in days of oxygen need, length of intensive care unit stays, less need for mechanical ventilation, accelerated recovery, and reduced mortality when the doses are 1.5 mg daily for 5 days, then 1 mg for 14 days. 32 Karakaş et al noted, even when comparing low doses of colchicine of 1 with 0.5 mg per day, beneficial effect of higher colchicine dosages. 33 T A B L E 7 Pooled data, separated by initial loading dose.…”

Section: Two Different Strategies For Treating Covid-19mentioning

confidence: 99%

See 2 more Smart Citations

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

Tiholov,

Lilov,

Georgieva

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

BackgroundPrevious research done in Bulgaria demonstrated a fivefold reduction in mortality from COVID‐19 with increased doses of colchicine from two hospitals in the country. We report here a further 333 cases of COVID‐19 inpatients, treated with different doses of colchicine and its effect on mortality.Materials and MethodsA case‐control comparison from two additional hospitals was conducted between increased doses of colchicine and added bromhexine to standard of care (SOC) versus current SOC. Risk and odds ratio, as well as subgroup analysis, was conducted with newly reported data, alongside aggregate data from all hospital centers to determine the extent of mortality reduction in COVID‐19 inpatients.ResultsThere was a clear reduction in the mortality of inpatients with increasing doses of colchicine—between twofold and sevenfold. Colchicine loading doses of 4 mg are more effective than those with 2 mg. Despite these doses being higher than the so‐called “standard doses,” colchicine inpatients experienced lower mortality than SOC patients (5.7% vs. 19.53%). This mortality benefit was evident in different age subgroups, with a 4‐mg loading dose of colchicine proving slightly superior to a 2‐mg loading dose. Colchicine led to an overall relative risk reduction of 70.7%, with SOC patients having 3.91 higher odds of death. The safety of the doses was not different than the reported in the summary of product characteristics.ConclusionInpatients in Bulgaria with added colchicine and bromhexine to SOC achieved better clinical and mortality outcomes than those on SOC alone. These results question the World Health Organization—recommended strategy to inhibit viral replication. We posit that our treatment strategy to inhibit the Severe acute respiratory syndrome coronavirus 2 entry into the cell with inhaled bromhexine and the hyperactivated NLRP3 inflammasome with higher doses of colchicine, prevents the development of cytokine storm. The timing of the initiation of treatment seems critical.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Two Different Strategies For Treating Covid-19mentioning

confidence: 99%

See 1 more Smart Citation

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

Tiholov,

Lilov,

Georgieva

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

show abstract

“…We have determined that over 50% of the studies observed no statistically significant reduction in mortality, symptom limitation, hospitalization, oxygen supply requirements, or inflammation reduction. The majority of these studies were randomized controlled trials (RCTs), and the highest-quality study with a large sample size confirmed this conclusion [ 17 , 25 , 30 , 32 , 33 ], except for one study that had a small sample size and mainly included obese patients among the 72 participants, thus limiting the generalizability of its findings [ 14 ]. However, it is worth noting that most studies supporting the use of colchicine were conducted before the emergence of the Delta and Omicron variants of concern (VOCs), which may have influenced the severity of cases.…”

Section: Discussionmentioning

confidence: 99%

Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review

Sharaf¹,

Ashmawy²,

Saleh³

et al. 2023

Medicina

View full text Add to dashboard Cite

Background: Colchicine has been proposed as a cytokine storm-blocking agent for COVID-19 due to its efficacy as an anti-inflammatory drug. The findings of the studies were contentious on the role of colchicine in preventing deterioration in COVID-19 patients. We aimed to evaluate the efficacy of colchicine in COVID-19-hospitalized patients. Design: A retrospective observational cohort study was carried out at three major isolation hospitals in Alexandria (Egypt), covering multiple centers. In addition, a systematic review was conducted by searching six different databases for published studies on the utilization of colchicine in patients with COVID-19 until March 2023. The primary outcome measure was to determine whether colchicine could decrease the number of days that the patient needed supplemental oxygen. The secondary outcomes were to evaluate whether colchicine could reduce the number of hospitalization days and mortality rate in these patients. Results: Out of 515 hospitalized COVID-19 patients, 411 were included in the survival analysis. After adjusting for the patients’ characteristics, patients not receiving colchicine had a shorter length of stay (median: 7.0 vs. 6.0 days) and fewer days of supplemental oxygen treatment (median: 6.0 vs. 5.0 days), p < 0.05, but there was no significant difference in mortality rate. In a subgroup analysis based on oxygen equipment at admission, patients admitted on nasal cannula/face masks who did not receive colchicine had a shorter duration on oxygen supply than those who did [Hazard Ratio (HR) = 0.76 (CI 0.59–0.97)]. Using cox-regression analysis, clarithromycin compared to azithromycin in colchicine-treated patients was associated with a higher risk of longer duration on oxygen supply [HR = 1.77 (CI 1.04–2.99)]. Furthermore, we summarized 36 published colchicine studies, including 114,878 COVID-19 patients. Conclusions: COVID-19-hospitalized patients who were given colchicine had poorer outcomes in terms of the duration of supplemental oxygen use and the length of their hospital stay. Therefore, based on these findings, the use of colchicine is not recommended for COVID-19-hospitalized adults.

show abstract

Natural compounds from medicinal plants against COVID-19

Kolodnitsky,

Ionov,

Gravel

et al. 2023

Explor Drug Sci

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), known to cause the coronavirus disease 2019 (COVID-19), was declared a pandemic in early 2020. During the past time, several infections control methods have been developed. Nevertheless, all of them have certain limitations: uncertainty in duration, limited efficacy of vaccines, and lack of effective drugs for COVID-19 treatment. So, the issue of creating drugs for symptomatic and etiotropic therapy is still relevant. This review summarizes the current knowledge of using natural compounds as anti-SARS-CoV-2 agents by analysing the results of in vitro studies and completed clinical trials (CTs). Also, this work highlighted the most active molecules and discussed the possibility of using some compounds in clinical practice.

show abstract

Effect of combined use of ivermectin and colchicine in COVID-19 patients

Cited by 3 publications

References 29 publications

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

Oxygen Saturation in Hospitalized COVID-19 Patients and Its Relation to Colchicine Treatment: A Retrospective Cohort Study with an Updated Systematic Review

Natural compounds from medicinal plants against COVID-19

Contact Info

Product

Resources

About